HoneyBear Biosciences Won the ‘Best ADC Developer in Taiwan’ Award in 2025 ABEA Competition
Ms. Sarina Lin,
Vice Chairwoman of HoneyBear Biosciences
(middle) and
Dr. Chuang, Simon, Shih-Hsien, CEO of HoneyBear Biosciences(right),
were invited to attend 2025 Asia Pacific Biopharma Excellence Awards (ABEA) awarding ceremony held on March 12th, 2025 in Singapore and awarded as the "Best ADC Developer in Taiwan".
Vice Chairwoman of HoneyBear Biosciences
(middle) and
Dr. Chuang, Simon, Shih-Hsien, CEO of HoneyBear Biosciences(right),
were invited to attend 2025 Asia Pacific Biopharma Excellence Awards (ABEA) awarding ceremony held on March 12th, 2025 in Singapore and awarded as the "Best ADC Developer in Taiwan".
HoneyBear Biosciences Inc. (hereinafter referred to as HoneyBear) exclusively owns and has multiple patents for the CoNectarTM technology platform, which is gradually drawing attention from international peers. The company's CEO, Dr. Chuang, Simon, Shih-Hsien, was invited to Singapore to give a keynote speech at the ADC Congress Asia on March 12th, 2025. On the same day, he and Sarina Lin, Vice Chairwoman of HoneyBear, attended the awarding ceremony as the winner of 2025 Asia Pacific Biopharma Excellence Awards (ABEA) and awarded as the "Best ADC Developer in Taiwan".
HoneyBear won the 2025 Asia Pacific Biopharma Excellence Awards (ABEA) competition and was recognized as the "Best ADC Developer in Taiwan". The awarding ceremony was held at 7 PM of March 12, 2025, at the Sands Expo & Convention Centre, Singapore.
Sarina said: "HoneyBear is a rising star in the biotech industrial territory. We’ve just completed the fundraising in November 2024, receiving high recognition and substantial investments from venture capital firms and investors. Our R&D team and our professional leadership team, with expertise in drug manufacturing, business management, and marketing etc., ensure the company is managed by an A team so HoneyBear's performance will be even more noticeable thereafter. In the future, we will continue to focus on R&D and plan to complete the first Investigational New Drug (IND) clinical trial application by 2026, officially joining in the rank of new drug development."
She added: "As we’re continuously and rapidly demonstrating excellent results, we believe more investments will flow in to reinforce the company's operational efficiency and support Honeybear to get exposure in the global market."
HoneyBear won the 2025 Asia Pacific Biopharma Excellence Awards (ABEA) competition and was recognized as the "Best ADC Developer in Taiwan". The awarding ceremony was held at 7 PM of March 12, 2025, at the Sands Expo & Convention Centre, Singapore.
Sarina said: "HoneyBear is a rising star in the biotech industrial territory. We’ve just completed the fundraising in November 2024, receiving high recognition and substantial investments from venture capital firms and investors. Our R&D team and our professional leadership team, with expertise in drug manufacturing, business management, and marketing etc., ensure the company is managed by an A team so HoneyBear's performance will be even more noticeable thereafter. In the future, we will continue to focus on R&D and plan to complete the first Investigational New Drug (IND) clinical trial application by 2026, officially joining in the rank of new drug development."
She added: "As we’re continuously and rapidly demonstrating excellent results, we believe more investments will flow in to reinforce the company's operational efficiency and support Honeybear to get exposure in the global market."
